{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:53:11Z","timestamp":1793735591550,"version":"4.6.1"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The prognosis of chronic myelogenous leukemia (CML-CP) in chronic phase has improved dramatically since the introduction of imatinib. In addition to imatinib, second- and third-generation tyrosine kinase inhibitors (TKIs) and a novel allosteric inhibitor, asciminib, are now available. During long-term TKI therapy, the optimal selection of TKI therapy for individual patients requires the understanding of specific patterns of toxicity profile to minimize chronic toxicity and the risk of adverse events, including pulmonary arterial hypertension, pleural effusion, and cardiovascular events. Given the high efficacy of TKI therapy, dose modifications of TKI therapy reduce the risk of toxicities and improves quality of life during therapy. In this review article, we summarize the characteristics and adverse event profile of each TKI and dose modifications in patients with CML-CP and discuss future perspectives in the treatment of CML-CP.<\/jats:p>","DOI":"10.3389\/fonc.2022.1021662","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T09:29:27Z","timestamp":1665048567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Kota","family":"Yoshifuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"iv261","DOI":"10.1093\/annonc\/mdy159","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Hochhaus","year":"2018","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.12.003","article-title":"Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction","volume":"16","author":"Sasaki","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29745","article-title":"Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13936","article-title":"Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes","volume":"173","author":"Jain","year":"2016","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30197","article-title":"A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase","volume":"122","author":"Takahashi","year":"2016","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03127-5","article-title":"Current status and novel strategy of CML","volume":"113","author":"Morita","year":"2021","journal-title":"Int J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.61.1179","article-title":"Chronic myeloid leukemia: update on treatment and survival prediction","volume":"61","author":"Sasaki","year":"2020","journal-title":"Rinsho Ketsueki"},{"key":"B19","doi-asserted-by":"publisher","first-page":"839915","DOI":"10.3389\/fonc.2022.839915","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in the real-life","volume":"12","author":"Iurlo","year":"2022","journal-title":"A Campus CML Study Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02095.x","article-title":"PDGF-c and -d and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries","volume":"39","author":"Karvinen","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04057-2","article-title":"Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion","volume":"599","author":"Sun","year":"2021","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11523-011-0204-7","article-title":"Cardiovascular toxicity of anti-angiogenic drugs","volume":"6","author":"des Guetz","year":"2011","journal-title":"Target Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835563","article-title":"Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter front-line TKIs study (KIARO study)","volume":"12","author":"Sicuranza","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a","article-title":"Discovery of n-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00277-017-3144-1","article-title":"Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series","volume":"97","author":"Iurlo","year":"2018","journal-title":"Ann Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.07.005","article-title":"Frontline dasatinib treatment in a \"Real-life\" cohort of patients older than 65 years with chronic myeloid leukemia","volume":"18","author":"Latagliata","year":"2016","journal-title":"Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1971292","article-title":"Long term follow-up of frontline dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study","volume":"60","author":"Stagno","year":"2021","journal-title":"Acta Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1701694","DOI":"10.1183\/13993003.01694-2017","article-title":"First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension","volume":"51","author":"Daccord","year":"2018","journal-title":"Eur Respir J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02736-5","article-title":"Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)","volume":"110","author":"Nagafuji","year":"2019","journal-title":"Int J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the framingham heart study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel src-abl inhibitor, against imatinib-resistant bcr-abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"B59","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of src and abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206797","article-title":"Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German chronic myeloid leukemia-study IV","volume":"104","author":"Michel","year":"2019","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2839-z","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes","year":"2017","journal-title":"Ann Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","author":"La Ros\u00e9e","year":"2013","journal-title":"Ann Hematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br J Haematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.V130.Suppl_1.318.318","article-title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: A real life observational study (NILO-RED)","volume":"130","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.02.013","article-title":"Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the phase IIIb ENESTswift study","volume":"67","author":"Hiwase","year":"2018","journal-title":"Leuk Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood-2019-127029","article-title":"Bosutinib in the real-life treatment of chronic phase chronic myeloid leukemia (CML) patients aged < 65 years Resistant\/Intolerant to frontline tyrosine-kynase inhibitors","volume":"134","author":"Latagliata","year":"2019","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: A safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3337-2","article-title":"Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice","volume":"97","author":"Breccia","year":"2018","journal-title":"Ann Hematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2517","article-title":"Upfront low-dose ponatinib (15 mg\/day) for multi-TKI resistant chronic myeloid leukemia","volume":"36","author":"Tefferi","year":"2018","journal-title":"Hematol Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13408","article-title":"The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data","volume":"105","author":"Luciano","year":"2020","journal-title":"Eur J Haematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25908","article-title":"Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs","volume":"95","author":"Iurlo","year":"2020","journal-title":"Am J Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26047","article-title":"The LEukemia artificial intelligence program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: Outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33539","article-title":"Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib","volume":"127","author":"Morita","year":"2021","journal-title":"Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-021-01106-1","article-title":"Impact of frontline treatment approach on outcomes of myeloid blast phase CML","volume":"14","author":"Saxena","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.025","article-title":"Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome","volume":"21","author":"Morita","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16245","article-title":"Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia","volume":"187","author":"Alfayez","year":"2019","journal-title":"Br J Haematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"Shoukier","year":"2021","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02620-2","article-title":"Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"109","author":"Sasaki","year":"2019","journal-title":"Int J Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1159\/000513925","article-title":"Two cases of possible familial chronic myeloid leukemia in a family with extensive history of cancer","volume":"144","author":"Aitken","year":"2021","journal-title":"Acta Haematol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3390\/cancers14102533","article-title":"Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects","volume":"14","author":"Senapati","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1021662\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T09:29:32Z","timestamp":1665048572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1021662\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":96,"alternative-id":["10.3389\/fonc.2022.1021662"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1021662","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"1021662"}}